World's Best Scientists 2026 revealed!
Per Eystein Lønning

Per Eystein Lønning

D-Index & Metrics

Medicine

D-Index
86
Citations
74263
World Ranking
13828
National Ranking
64

Per Eystein Lønning publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Per Eystein Lønning sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 492 publications — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Per Eystein Lønning D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Per Eystein Lønning sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 86 D-Index — 31st percentile

31% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Per Eystein Lønning is affiliated with Haukeland University Hospital in Norway and has contributed to the fields of biochemistry, genetics, molecular biology, and medicine through numerous research publications. Their work spans several subfields including molecular biology, oncology, cancer research, genetics, and hepatology. The main research topics they engage with include epigenetics and DNA methylation, cancer genomics and diagnostics, PARP inhibition in cancer therapy, BRCA gene mutations in cancer, hepatocellular carcinoma treatment and prognosis, colorectal cancer treatments and studies, and DNA repair mechanisms.

The scientist's recent papers cover key subjects within oncology and molecular biology. Notable publications include:

  • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer (2020, Annals of Oncology)
  • Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials (2023, The Lancet)
  • Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer (2022, JAMA Oncology)
  • C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer (2022, Nature Communications)
  • Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers (2022, Clinical Cancer Research)

Frequent co-authors collaborating with Lønning include:

  • Stian Knappskog
  • Oleksii Nikolaienko
  • Hans Petter Eikesdal
  • Bjørnar Gilje
  • Egil Støre Blix

Their work has been published repeatedly in several scientific venues. These include:

  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Epigenetics

Per Eystein Lønning's contributions involve research into key mechanisms underlying cancer biology such as DNA repair, epigenetic regulation, and responses to targeted therapies. Their median engagement in research topics related to PARP inhibition and BRCA gene mutations highlights a focus on personalized therapy approaches for breast and ovarian cancers.

Best Publications

  • Molecular portraits of human breast tumours

    Charles M. Perou;Therese Sørlie;Michael B. Eisen;Matt van de Rijn

  • Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

    Therese Sørlie;Charles M. Perou;Robert Tibshirani;Turid Aas

  • Repeated observation of breast tumor subtypes in independent gene expression data sets

    Therese Sørlie;Robert Tibshirani;Joel Parker;Trevor Hastie

  • A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

    R. C Coombes;E. Hall;L. J. Gibson;R. Paridaens

  • Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors

    Jonathan R. Pollack;Therese Sørlie;Charles M. Perou;Christian A. Rees

  • Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

    RC Coombes;LS Kilburn;CF Snowdon;R Paridaens

  • Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

    Turid Aas;Anne Lise Børresen;Stephanie Geisler;Birgitte Smith-Sørensen

  • Subclonal diversification of primary breast cancer revealed by multiregion sequencing

    Lucy R. Yates;Moritz Gerstung;Stian Knappskog;Christine Desmedt

  • Long-term Cultures of Bone Marrow–Derived Human Mesenchymal Stem Cells Frequently Undergo Spontaneous Malignant Transformation

    Gro Vatne Røsland;Agnete Svendsen;Anja Torsvik;Ewa Sobala

  • Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays

    Jonathan R. Pollack;Charles M. Perou;Therese Sorlie;Ash A. Alizadeh

  • Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study

    Jürgen Geisler;Ben Haynes;Gun Anker;Mitch Dowsett

  • Genomic Evolution of Breast Cancer Metastasis and Relapse

    Lucy R. Yates;Stian Knappskog;Stian Knappskog;David Wedge;David Wedge;James H.R. Farmery

  • Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

    Anna Bergamaschi;Young H. Kim;Pei Wang;Pei Wang;Therese Sørlie

  • Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

    Stephanie Geisler;Per Eystein Lønning;Turid Aas;Hilde Johnsen

  • Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial

    Per Eystein Lønning;Emilio Bajetta;Robin Murray;Michèle Tubiana-Hulin

  • Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Angelo Di Leo;Stephen Johnston;Keun Seok Lee;Eva Ciruelos

  • Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

    J. Geisler;N. King;M. Dowsett;L. Ottestad

  • In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

    J Geisler;N King;G Anker;G Ornati

  • Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter.

    Anja Torsvik;Gro V. Røsland;Agnete Svendsen;Anders Molven

  • Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer

    Per E. Lønning;Jürgen Geisler;Lars E. Krag;Bjørn Erikstein

Frequent Co-Authors

Stian Knappskog
Stian Knappskog University of Bergen
Anne Lise Børresen-Dale
Anne Lise Børresen-Dale Oslo University Hospital
Johan R. Lillehaug
Johan R. Lillehaug University of Bergen
Mitch Dowsett
Mitch Dowsett Breast Cancer Research Foundation
Vessela N. Kristensen
Vessela N. Kristensen Oslo University Hospital
Lars A. Akslen
Lars A. Akslen University of Bergen
Per Magne Ueland
Per Magne Ueland University of Bergen
Lars J. Vatten
Lars J. Vatten Norwegian University of Science and Technology
Kristian Hveem
Kristian Hveem Norwegian University of Science and Technology
Pål Romundstad
Pål Romundstad Norwegian University of Science and Technology

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a healthcare career but aren’t ready to commit to a full MD program, there are many accessible online degrees and certifications that can open doors in the medical field. Online learning offers flexibility and affordability, making it easier to balance your studies with work or other commitments.

One popular route is pursuing HIM programs (Health Information Management), which prepare graduates for roles at the intersection of healthcare, technology, and administration. For those seeking entry-level positions, the cheapest medical coding certification online options provide a pathway into the growing field of medical billing and coding.

Aspiring nurses can benefit from the nurse practitioner programs available online, which offer advanced clinical knowledge for those looking to become independent healthcare providers. For a more affordable start, the cheapest online nursing program options can help you launch your nursing career without incurring excessive debt.

Exploring these alternative pathways can be a practical step toward joining the medical community, gaining credentials, and building experience—all from the convenience of your home.

Best Scientists Citing Per Eystein Lønning

Trending Scientists

Recently Published Articles